TuesdayJun 09, 2026 10:00 am

Hospitals Take the Lead in Tackling Health Care Access and Affordability

Hospitals have come under the spotlight as public concern about the health care cost crisis reaches unprecedented levels. The president of the American Hospital Association (AHA) wrote an article last week outlining how hospitals are taking steps to ensure that access and affordability issues are addressed so that Americans can continue to enjoy the high quality of care that they have come to expect from the health care system.  Rick Pollack explained that hospitals face numerous challenges, such as having to absorb a sizeable fraction of the increasing cost of providing medical services to Americans. This comes as reimbursements for programs like Medicare and Medicaid haven’t risen…

Continue Reading

MondayJun 08, 2026 9:45 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for Multiple Sclerosis Treatment

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS  therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body. The company announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated. Quantum BioPharma reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food…

Continue Reading

FridayJun 05, 2026 10:30 am

Oncotelic Therapeutics Inc. (OTLC) Combines Nanomedicine, AI, and Robotics to Advance Precision Oncology and Rare Disease Innovation

OTLC continues to advance its Deciparticle nanomedicine platform, with expanding international development initiatives supporting future therapeutic and commercial opportunities. The company’s PDAOAI ecosystem now incorporates 28 million scientific abstracts and is being deployed into real-world pharmaceutical automation applications through TechForce Robotics. The company is leveraging AI, nanomedicine, and automation to accelerate therapies for cancer and rare diseases. Oncotelic Therapeutics (OTCQB: OTLC) is strategically placing itself at the nexus of precision oncology, advanced automation, and artificial intelligence. Through its PDAOAI artificial intelligence ecosystem, Deciparticle(TM) nanomedicine platform, and emerging robotics initiatives, the company is quickly building an integrated technology portfolio built to improve…

Continue Reading

FridayJun 05, 2026 10:00 am

LA Calls for Infectious Diseases Vigilance During World Cup

This month and in July, the SoFi Stadium in Los Angeles County will host several World Cup matches, and other tournament-related activities will take place within the county. Accordingly, the health department of the county has put health care providers on notice to be alert for infectious diseases during the tournament.  SoFi Stadium will host eight World Cup matches, and the global tournament is coinciding with Pride Month. Because of these events, lots of national and international travelers, at least 150,000, are expected to descend on LA County, and that could provide ideal conditions for many infectious diseases to spread.  County health officials warn that the massive…

Continue Reading

FridayJun 05, 2026 9:45 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Targets Growing Need for Non-Invasive Intoxication Detection

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics is developing AI-powered voice analysis technology designed to detect drug and alcohol impairment from short speech samples. The platform analyzes more than 140 acoustic markers and has been trained on a dataset exceeding 50 million data points. Mining operations in South America represent the company’s initial commercial focus, where workforce safety and high-volume screening requirements create operational challenges. Potential applications extend beyond mining into aviation, construction, law enforcement, call centers, transportation, and mental health settings. The global alcohol and drug testing devices market is…

Continue Reading

ThursdayJun 04, 2026 10:00 am

Pediatric Brain Tumors Spread Faster as Immune Cells Build Enabling Scaffolding

Scientists have identified a potential mechanism through which aggressive pediatric brain tumors called diffuse midline gliomas spread. The researchers found that immune cells within the brain, called microglia, produce proteins called fibronectin that help the tumors to progress.  The findings, published in the Cell Death & Disease journal, offer a possible mechanism that can be targeted in efforts to develop effective treatments against these tumors.  Conducted by a team at Karolinska Institutet, the researchers aimed to investigate what role microglia played in tumor progression and how these cells are impacted by the cancer. In their study, the team found that when microglia are exposed to diffuse midline glioma (DMG) cells, they respond by producing large quantities of fibronectin and…

Continue Reading

ThursdayJun 04, 2026 9:00 am

Regentis Biomaterials Ltd. (NYSE American: RGNT): Could GelrinC Become the First Widely Adopted Off-the-Shelf Regenerative Cartilage Repair Platform?

Humanitas collaboration supports Regentis’ physician adoption strategy and broader commercial infrastructure across the European market. GelrinC targets a large orthopedic market that currently lacks an approved off-the-shelf regenerative cartilage repair solution. Pivotal FDA enrollment, manufacturing scale-up, physician engagement initiatives and CE Mark status position the company toward multiple potential value-inflection milestones. Regenerative medicine has long promised to transform patient care, but investors often become most interested when innovative science begins transitioning toward commercial adoption. Regentis Biomaterials (NYSE American: RGNT) is approaching that transition with GelrinC(R), its cartilage regeneration platform targeting a large orthopedic market where treatment alternatives continue to involve meaningful trade-offs. The…

Continue Reading

WednesdayJun 03, 2026 9:45 am

Earth Science Tech Inc. (ETST) Pairs Healthcare Expansion with Aggressive Share Repurchases

Earth Science Tech has evolved into a diversified healthcare holding company with operations spanning telemedicine, compounding pharmacies, clinical support services and healthcare fulfillment. In addition, the company has actively reduced its share count through a series of share repurchases documented in SEC filings and share structure records. Earth Science Tech repurchased 3.7 million shares over the nine months ended December 31, 2025, spending approximately $647,000. Management continues to emphasize shareholder value through balance-sheet management alongside acquisitions and operating growth. The company is scheduled to present to investors at the Planet MicroCap Las Vegas 2026 conference in June. For many investors…

Continue Reading

WednesdayJun 03, 2026 9:00 am

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as key…

Continue Reading

WednesdayJun 03, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. The growing burden of neurological disease has intensified industry-wide interest in therapies capable of protecting neurons, preserving brain function and addressing disease progression at a biological level. Quantum BioPharma’s flagship pharmaceutical subsidiary, Lucid Psycheceuticals Inc., is advancing LUCID-MS, a patented new chemical entity being developed for an unmet need in multiple sclerosis. The company has also expanded its presence in a consumer ready product in the field of alcohol health and sobriety through its involvement with unbuzzd(TM), an innovative, clinically validated alcohol metabolism accelerator designed to…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000